Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results
posted on 2021-12-08, 16:08authored byAdis journals on behalf of, Cristian Guja, Francesco Giorgino, Lawrence Blonde, Amar Ali, Martin Prázný, Juris J. Meier, Elisabeth Souhami, Robert Lubwama, Chen Ji, Julio Rosenstock
The above infographic represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).